厄洛替尼治疗化疗后进展的晚期非小细胞肺癌的近期疗效观察

Erlotnib in the treatment of advanced non-small cell lung cancer failed to previous chemotherapy

目的观察厄洛替尼治疗化疗后进展的晚期非小细胞肺癌（NSCLC）的疗效和不良反应。方法化疗后进展的12例晚期NSCLC患者，口服厄洛替尼150mg／d，1个月后进行疗效评价。疾病无进展者继续服用，之后每月对接受治疗者进行疗效评价，并密切观察不良反应。结果12例患者均可评价疗效，其中完全缓解1例，部分缓解2例，疾病无变化4例，疾病进展5例；有效率为25．0％（3／12），疾病控制率为58．3％（7／12），临床受益率为41．7％（5／12）。厄洛替尼治疗的主要不良反应为皮疹和腹泻，全组无一例患者因不能耐受不良反应而终止治疗。结论厄洛替尼对化疗后进展的晚期NSCLC具有一定的疗效，且不良反应轻，患者能够耐受。

Objective To investigate the efficacy and side effect of erlotnib for refractory patients with advanced non-small cell lung cancer （NSCLC） failed to previous chemotherapy. Methods Twelve patients with chemo-refractory NSCLC were enrolled into this study. Erlotnib was administered at a dose of 150 mg orally once a day for a month. The assessment was carried out every month by intensive clinical observation and monthly CT scan until disease progression or intolerable toxicity occurred. Results All the 12 patients were evaluable. The response rate including complete and partial responses （CR and PR） was 25.0% （3/12）. The disease control rate including complete, partial response and stable disease （CR, PR and NC） was .58.3% （7/12）. The clinical benefit rate was 41.7% （5/12）. The main side effects included skin rash and diarrhea. No patient was withdrawn from the treatment due to intolerable toxicities. Conclusion Erlotnib is effective and tolerable in the treatment of patients with advanced NSCLC failed to previous chemotherapy.